Moleculin Biotech (NASDAQ:MBRX) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings data on Thursday. The company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.55) by $0.15, FiscalAI reports.

Moleculin Biotech Trading Up 8.0%

Shares of MBRX opened at $0.62 on Friday. The business’s 50 day moving average is $2.06 and its 200 day moving average is $2.51. The company has a market capitalization of $4.38 million, a PE ratio of -0.03 and a beta of 1.83. Moleculin Biotech has a 12-month low of $0.16 and a 12-month high of $17.23.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on MBRX. Wall Street Zen lowered Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.